Aktie A2QP1Y SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen SciClone Pharmaceuticals (Holdings) Limited

Aktien

A2QP1Y

KYG4271B1023

6600

Markt geschlossen - Hong Kong S.E.
Andere Börsenplätze
 10:08:35 19.04.2024 		% 5 Tage % 1. Jan.
18 HKD -0,22 % Intraday Chart für SciClone Pharmaceuticals (Holdings) Limited +0,45 % +29,31 %
01.04. SciClone Pharmaceuticals verzeichnet 31% Gewinnanstieg im Jahr 2023 MT
28.03. Sciclone Pharmaceuticals (Holdings) Limited kündigt Änderungen in der Geschäftsführung an CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Sciclone Pharmaceuticals to Dispatch Privatization Documents by May 31
SciClone Pharmaceuticals Logs 31% Increase in 2023 Profit
Sciclone Pharmaceuticals Limited Announces Executive Changes
SciClone Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023
SciClone Completes Patient Enrollment for Urinary Tract Infection Drug's Phase 3 Trial; Shares Rise 3%
SciClone Pharmaceuticals Limited Announces Phase III Clinical Trial of Vaborem® Completed Subject Enrollment in China
Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer
SciClone Signs Licensing Deal with Menarini for Breast Cancer Drug; Shares Rise 3%
SciClone Pharmaceuticals Limited and Menarini Establish License and Collaboration Agreement for Orserdu in China
SciClone Pharmaceuticals' Profit Jumps 18.4% in H1
SciClone Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023
SciClone Pharmaceuticals Doses First Patient in Phase 3 Study for Urinary Tract Infection Injection
SciClone Pharmaceuticals Limited Announces First Subject Dosed in Phase III Clinical Trial of Vaborem in China
SciClone Commercially Launches Neuroblastoma Treatment in China
SciClone Pharmaceuticals Limited Announces Commercial Launch of DANYELZA in China
SciClone Pharmaceuticals Limited commences an Equity Buyback Plan for 61,829,507 shares, representing 10% of its issued share capital, under the authorization approved on May 25, 2023.
SciClone Pharmaceuticals Limited Approves a Final Dividend for the Year Ended December 31, 2022
Sciclone Pharmaceuticals Limited Elects Ms. Pan Rongrong as an Executive Director of the Company
SciClone Pharmaceuticals Limited's Equity Buyback announced on May 20, 2022, has expired.
Sciclone Pharmaceuticals Limited Announces Retirement of SHI Cen as Non-Executive Director
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2QP1Y Aktie
  4. Nachrichten SciClone Pharmaceuticals (Holdings) Limited
  5. Andere Sprachen